Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial
|
|
- Ralph Butler
- 5 years ago
- Views:
Transcription
1 DOI: / Epidemiology Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial N Cherry, a R McNamee, b A Heagerty, c H Kitchener, d P Hannaford e a Division of Preventive Medicine, University of Alberta, Edmonton, AB, Canada b School of Community-based medicine, University of Manchester, Manchester, UK c Cardiovascular Research Group, University of Manchester, Manchester, UK d Institute of Cancer Sciences, University of Manchester, Manchester, UK e School of Medicine and Dentistry, University of Aberdeen, Aberdeen, UK Correspondence: Dr N Cherry, Division of Preventive Medicine, University of Alberta, Edmonton, AB T6G 2T4, Canada. nicola.cherry@ualberta.ca Accepted 25 October Published Online 18 February Objective To compare health outcomes during 14-year observational follow-up in women initially randomised to unopposed estrogen or placebo. Design At recruitment to the Estrogen for the Prevention of Re-Infarction Trial (ESPRIT) women were assigned to estradiol valerate: 2 mg or placebo treatment for 2 years. Setting Women were recruited from 35 hospitals in the northwest of England and Wales in July 1996 February Sample Women aged surviving their first myocardial infarction. Methods All women were followed by data linkage to UK mortality and cancer records; mean follow-up 14.1 and 12.6 years, respectively. In an intention-to-treat analysis, hazard ratios (HRs) were computed, overall and stratified by age at recruitment. Outcome measures Death (all-cause, cardiac disease, stroke or cancer) and cancer incidence (any, breast or endometrium). Results There were 418 deaths in 1017 women randomised. The all-cause mortality HR of 1.07 (95% CI ) indicated no significant difference between treatment groups. Women aged years at recruitment had lower HRs than women aged years for all outcomes except ischaemic heart disease. Among 149 incident cancers there were seven cases of breast cancer in the intervention arm and 15 in the placebo; HR 0.47 (95% CI ). There were no deaths from endometrial cancer but three incident cases, one in the active arm and two in placebo. Conclusions These results suggest that unopposed estrogen may be used safely by women with an intact uterus surviving a first myocardial infarction. Keywords Cancer, estrogen, randomised controlled trial. Please cite this paper as: Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG 2014;121: Introduction The ESPRIT trial 1 was designed to investigate whether estrogen (estradiol valerate) reduced the risk of re-infarction, cardiac death or all-cause mortality in postmenopausal women recruited at the time of hospital admission for a first myocardial infarction (MI). Few other trials of the health effects of hormone replacement therapy (HRT) have used estrogen without progesterone (unopposed estrogen) in women with an intact uterus. The recent Cochrane review 2 lists only two (EPAT 3 and PEPI 4 ), both of which used surrogate markers of disease rather than clinical outcomes. The largest trial of unopposed estrogen (Women s Health Initiative Estrogen-Alone Trial [WHI E-A] 5 ), which recruited women in good health, initially included women with an intact uterus in the unopposed estrogen arm but later changed the protocol because of concerns about endometrial hyperplasia. 6 The ESPRIT trial used estrogen without progesterone for all women in the treatment arm, including those with an intact uterus, because of concern about the safety of using progesterone in women with recent MI. The follow-up described in this report was planned primarily to determine whether this use of unopposed estrogen was detrimental, specifically whether there was any evidence of excess endometrial cancer that might be attributed to the intervention. 700 ª 2014 Royal College of Obstetricians and Gynaecologists
2 Safety of unopposed estrogen in the ESPRIT trial Recently published data from the WHI E-A trial has demonstrated a protective effect of unopposed conjugated equine estrogens (CEE) on invasive breast cancer in women of all ages in that trial and, in younger women (aged years at enrolment), on the incidence of coronary heart disease (CHD), MI and death (all causes), with a trend towards more adverse outcomes in those over 60 years. 7 Although smaller than WHI E-A, ESPRIT, with 1017 subjects randomised, is larger than any other trial using unopposed estrogen. Continued follow-up of the women recruited provided the opportunity to assess whether the WHI-E-A results on incident breast cancer and death from all causes, stratified by age, were found also in women recruited in a different country and exposed to a different type of estrogen (estradiol valerate rather than CEE used in the WHI E-A). Methods As described in the earlier report, women age years who had survived a first MI were recruited at the time of their hospitalisation for MI from 35 collaborating hospitals in the northwest of England and Wales between July 1996 and February Women who reported a history of cancer or use of hormone replacement therapy in the previous 12 months were excluded. Subjects were randomised to receive either one tablet of estradiol valerate (2 mg; n = 513) or placebo (n = 504), daily for 2 years. Each subject was followed up through their family physician at 3, 6, 12, 18 and 24 months from date of recruitment, with follow-up of the last recruit ending on 2 February The outcome of this initial active follow-up has been reported previously. 1 Given the unconventional use of unopposed estrogen in women with an intact uterus (373/513 in the active treatment arm), strict trial procedures sought to maximise the notification of all episodes of vaginal bleeding, and provide effective management of such episodes. 1 Women with vaginal bleeding during the trial were clinically assessed and, if appropriate, had a pipelle endometrial biopsy followed by a 14-day course of medroxyprogesterone acetate 20 mg, increased to three courses each lasting 14 days if the biopsy showed complex hyperplasia. When women with an intact uterus stopped active or placebo treatment, at 2 years after study entry or earlier, those who had not been investigated previously for vaginal bleeding were offered an endometrial biopsy. Women in the active arm who had not had a hysterectomy were also sent a letter each year for 5 years after stopping treatment to remind them to seek medical attention if they experienced vaginal bleeding. There was no attempt after the end of the 2-year intervention period to obtain information from women or their physicians about medication (including use of estrogen) or health events. However, all 1017 women were flagged at recruitment on the UK National Health Service central register so that deaths and cancers could be notified through record linkage. The analyses reported here are based on these notifications. Follow-up for this paper was to 31 December 2010 for cancer incidence (mean follow-up 12.6 years, range ) and to 30 June 2012 for mortality (mean follow-up 14.1 years, range ). Cancer incidence, vital status and cause of death were determined from data routinely collected by the Office of National Statistics for England and Wales, and by parallel systems in Scotland for women who had moved there after recruitment into the study. Cancer incidence data are routinely collected by regional cancer boards and forwarded to the national register with some delay (hence the shorter follow-up for this endpoint). Mortality is reported centrally with cause of death (both underlying and mentioned, i.e. a condition that contributed to but did not cause the death) on the death certificate coded routinely using the World Health Organization International Classification of Diseases (ICD) codes, version 9 until 2000 and version 10 in subsequent years. For this follow-up the outcomes of interest were death (all-cause) and deaths from ischaemic heart disease (ICD ; ICD-10 I20-I25), any cardiac diagnosis (ICD-9 codes , , , ; ICD-10 I05-I09, I20-I25, I26-I28, I30-I52), stroke (ICD 9: , ICD-10: I ), any cancer (ICD , ICD-10 C00-C97), breast cancer (ICD-9 174; ICD-10 C50) and endometrial cancer (ICD-9 182; ICD-10 C54.1). Incidence of cancer in this analysis, for any cancer, breast cancer and endometrial cancer, was taken from cancer notifications with the same ICD codes as those in the mortality analysis. Analysis Hazard ratios (HRs) comparing treatment arms were estimated using Cox regression. In the all-cause mortality analysis, data for those still alive at the end of follow-up period were treated as censored observations; for analysis of specific causes or cancer incidence, censoring was at the end of the follow-up period or time of death if earlier. All HRs were adjusted for age at risk, using six 5-year age bands (50 55 to 75 80). A binary variable indicated the randomised treatment arm; thus each analysis was by the intention to treat during the 2-year intervention phase. Each outcome was considered separately. For mortality, the analysis was first by underlying cause and then by any mention on the death certificate. For cancer incidence, the time to event for any cancer was taken as time to the first cancer if more than one had occurred: in situ and benign neoplasms were excluded. Confidence intervals (95% CI) were calculated. For each outcome the effect of treatment group was estimated for all women and then stratified by age at recruitment (age years [n = 301] or years [n = 716]): again, adjustment was made in 5-year bands for age at risk. Tests of whether the HRs differed sig- ª 2014 Royal College of Obstetricians and Gynaecologists 701
3 Cherry et al. nificantly between the two age groups were based on a test of interaction between age and treatment in the regression model. The HR for endometrial cancer was calculated only for those with an intact uterus at the time of recruitment. Results Mortality There were 418 deaths among the 1017 women recruited to ESPRIT, 214 among the 513 in the treatment arm and 204 among the 504 in the placebo arm (Table 1). The overall HR for all-cause mortality was 1.07 (95% CI: ) (Table 2). Heart disease was recorded as the underlying cause for 177 (42.3%) of the 418 deaths and as either the underlying cause or as a condition mentioned elsewhere on the death certificate ( any mention in the tables) in 269 (64.4%) deaths. Estimates of HRs (Table 2) for all women showed no significant detrimental or protective effect of treatment, although the ratios were above unity for heart disease and stroke. When stratified by age, women recruited at age years had lower HRs (except for IHD) than those aged years at recruitment, although none of the differences between age groups was significant (P > 0.05). Five deaths were attributed to breast cancer (one in the active treatment group, four in placebo) as the underlying cause. There were seven women with any mention of breast cancer on the death certificate, three in the active arm and four in placebo. Endometrial cancer was not reported on any death certificate, either as an underlying or as a mentioned cause. Although not an outcome specified a priori, three death certificates with codes for ovarian cancer (ICD ; ICD-10 C56) were noted, all in the active arm (P = 0.25, Fisher s exact test). Cancer incidence There were 149 incident malignant cancers among 142 women, plus 13 in situ or benign tumours (none breast or genital; excluded from the analysis). The HR was close to unity for any cancer (all types) among the 1017 women, with lower HRs for those under 60 years of age at recruitment (Table 2). There were 22 incident cases of breast cancer, seven in the treatment group and 15 in placebo. HRs for breast cancer were below unity for the treatment arm overall and for both younger and older women when examined separately, with women aged years having the smallest risk estimate (0.33). For the group as a whole, the (two-sided) probability of an HR of 0.47 or smaller, under the null hypothesis, was 0.097, having adjusted for age at risk. There were three incident cases of endometrial cancer (one in the active arm and two in placebo), giving an HR Table 1. Outcome by treatment group and age at recruitment Outcome Age All ages Active Placebo Active Placebo Active Placebo n = 167 n = 134 n = 346 n = 370 n = 513 n = 504 n % n % n % n % n % n % Death* All causes Underlying cause Ischaemic heart disease (IHD) Any heart disease Stroke Cancer all sites Any mention Ischaemic heart disease (IHD) Any heart disease Stroke Cancer all sites Cancer incidence** All sites Breast cancer *To 30 June **To 31 December ª 2014 Royal College of Obstetricians and Gynaecologists
4 Safety of unopposed estrogen in the ESPRIT trial Table 2. Hazard ratio (active/placebo) by age at recruitment (adjusted for age at risk) Outcome Age All ages HR 95% CI HR 95% CI HR 95% CI Death All causes Underlying cause Ischaemic heart disease (IHD) Any heart disease Stroke Cancer all sites Any mention Ischaemic heart disease (IHD) Any heart disease Stroke Cancer all sites Cancer incidence All sites Breast cancer of 0.52 (95% CI ) and one cervical cancer (placebo). Five ovarian cancers were listed, four in the active arm (P = 0.37, Fisher s exact test). Discussion Main findings This follow-up of ESPRIT was primarily to investigate whether any harm had been done by using unopposed estrogen in women with an intact uterus. No harm has been demonstrated. Although during the trial, more than half of the women in the active arm with a uterus reported bleeding, no woman was diagnosed with endometrial cancer during active follow-up. 1 The unexpected observation of more ovarian cancer in the treatment arm is consistent with chance and has not been reported in other trials. As in the initial report, there was no significant difference between women in the active and treatment arms on any of the outcomes considered. In the current analysis, the lowest HR (0.47, suggesting a protective effect of active treatment) was for incident breast cancer, with the likelihood of such an effect arising by chance being <0.10. For all the outcomes (except IHD as underlying cause) considered in this extended ESPRIT follow-up, the HR for women aged years at recruitment was lower than for older women. Strengths and limitations As all of the women were flagged for death and cancers at the NHS Central registries, we should have captured all such events occurring in the trial participants; in effect there was no loss to follow-up. Although our study had limited statistical power for some of the endpoints included in the analysis, it had 80% power to detect a 20% decrease in all-cause mortality. No increase in risk of endometrial cancer was seen in this study (HR = 0.52) but with a confidence interval the possibility of a true increase in risk cannot be excluded on the basis of these data alone. During the extended follow-up of the original trial, we did not obtain participant data on non-fatal clinical events other than cancer incidence. This trial cannot, therefore, add to reports of other outcomes (e.g. gall bladder disease, venous thrombo-embolism, non-fatal stroke) that have been associated with unopposed estrogen elsewhere. 2 Neither could we assess whether, over time, unopposed estrogen affects the risk of non-fatal myocardial re-infarction. Data were not available about use of hormone replacement therapy after the formal trial ended. Some women may have used these products subsequently, although the number is probably small due to the widespread publicity that occurred in the summer of 2002 concerning the premature cessation of the estrogen plus progestin trial of the Women s Health Initiative, 6 leading to regulatory advice in the UK to avoid long-term use. 8 The absence of adverse effect on the endometrium in this study is likely to be, in large part, a reflection of the management of bleeding during and at the end of the active intervention. 1 Eight women found to have atypical hyperplasia during the trial were immediately started on a 3-month course of cyclical medroxyprogesterone acetate: all endometrial abnormalities resolved and none of the women required a hysterectomy ª 2014 Royal College of Obstetricians and Gynaecologists 703
5 Cherry et al. during the 2 years of the trial. The conclusion of no adverse effect, therefore, should not be generalised to situations without such active management. Interpretation In its most recent follow-up, the WHI E-A found a significantly reduced HR for breast cancer in those randomised to unopposed estrogen (0.77: 95% CI ). 7 The size of the protective effect was much the same at 10.7 years as at 7.1 years of follow-up, but with more events increasing the trial s power, a stronger conclusion of benefit was possible. Younger women in the active treatment arm of the WHI E-A study had a similar reduction in risk of breast cancer as older women. In a recently reported trial from Denmark, 192 women aged years who had undergone hysterectomy were randomly assigned to take unopposed estrogen (n = 95) or to no treatment (n = 97) and followed up for death, cardiovascular disease and cancer for 16 years. 9 Those on unopposed estrogen as their active treatment were reported to have an HR (0.63: 95% CI ) for breast cancer similar to that in the WHI E-A trial. The lower breast cancer incidence in the women in ESPRIT is consistent with these earlier reports. The WHI E-A also showed greater benefit of active treatment in younger than in older women at 10.7 years of follow-up. Rates were lower for incident CHD, MI and death (all causes). 7 The incident data for CHD and MI is not comparable with ESPRIT, where all the women had been recruited post-mi, but the lower HR for death from all causes was seen in younger women in both studies. The WHI E-A found an increased risk of stroke at 7.1 years, 5 but by 10.7 years there was no significant increase in the active intervention group, overall or in any age-specific group. 7 In ESPRIT, clinical reports of stroke were somewhat higher in the intervention arm at the end of 2 years (risk ratio 1.64, 95% CI ). 1 Non-fatal strokes were not identified in the follow-up reported here, but there was only a small excess of deaths in which stroke appeared as an underlying or mentioned cause among those assigned to estrogen, again consistent with the findings from the larger US trial. Conclusion The ESPRIT trial was set up to examine whether estrogen prevented re-infarction in post-menopausal women. The results of both the initial trial and this extended follow-up did not suggest important deficit in cardiac events/mortality in the intervention arm and do not support the use of estrogen for prevention of cardiac mortality in this group. Importantly, there was no evidence that use of unopposed estrogen was harmful: its use by women with an intact uterus did not result in an excess risk of endometrial cancer. As such, if estrogen is indicated in elderly women with heart disease for reasons such as the control of menopausal symptoms, the use of unopposed estrogen may be considered. A recent Cochrane review concluded that for women in their 50s without a uterus taking estrogen-only HT for 5 6 years appears relatively safe and there may even be some health benefits. 2 Our results support this conclusion, even for women with a uterus, provided that there are processes in place for the investigation and management of any vaginal bleeding arising among users. Disclosure of interests PH has received research grants from Schering AG, and hospitality and speakers fees from Schering Health Care Limited. Contribution to authorship NC, RMcN and PH were responsible for the design of the original study, with AH contributing to decisions on cardiac aspects of the study and HK to the design and implementation of the gynaecological protocol. During the follow-up reported here, NC and then PH received notifications on deaths and incident cancers. RMcN carried out the statistical analyses. All authors contributed to the writing of the report. Details of ethics approval The trial, including follow-up via the Central Registry, was approved by the central ethics committee of the Royal College of General Practitioners, the research ethics committee of the University of Manchester and the local research ethics committees of the 35 collaborating hospitals in the northwest of England and north east Wales. Funding The initial trial was funded by the UK National Health Services Research and Development Programme on Cardiovascular Disease and Stroke through a grant to the University of Manchester. Medication (active and placebo) used as the intervention was supplied without charge by Schering AG. Additional support came from Schering Health Care Limited. Continued follow-up is supported by the University of Aberdeen. None of the funders has been involved with the collection, analysis or interpretation of data reported here. Acknowledgements None. & References 1 The Esprit team. Oestrogen therapy for the prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360: Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;(7):CD ª 2014 Royal College of Obstetricians and Gynaecologists
6 Safety of unopposed estrogen in the ESPRIT trial 3 Hodis HN, Mack WJ, Lobo RA, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo controlled trial. Ann Intern Med 2001;135: Writing group for the PEPI trial. Effects of estrogen or estrogen/ progestin regimes on heart disease risk factors in postmenopausal women. JAMA 1995;273: Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women s Health initiative randomized controlled trial. JAMA 2004;291: Writing group for the Women s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288: LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Margolis KL, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305: Medicines Control Agency (MCA) Committee on Safety of Medicines. New product information for hormone replacement therapy. Curr Probl Pharmacovigilance 2002;28: Schierbeck LL, Rejnmark l, Tofteng CL, Stilgren L, Eiken P, Moselilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409. Mini commentary on Estrogen-only treatment: an option for menopausal women with an intact uterus AM Kaunitz Department of Obstetrics and Gynecology, University of Florida College of Medicine, Jacksonville, FL, USA Conventional wisdom in the 1990s was that menopausal estrogen therapy (ET) prevented coronary artery disease. The ESPRIT investigators employed a 2-year estrogen-only regimen, oral estradiol valerate 2 mg (the equivalent of approximately 1.5 mg of oral micronised estradiol) (Timmer CJ, et al. Eur J Drug Metab Pharacokinet 1999;24:47 53), in women with coronary heart disease, regardless of whether a uterus was present. The long-term follow-up of this cohort does not support the use of ET to prevent a second myocardial infarction. However, ESPRIT s reassuring findings regarding the impact of ET on risk of breast and endometrial cancer will cause some to question our current paradigm of mandating combination estrogen-progestin hormone therapy (EPT) when treating bothersome menopausal symptoms in women with an intact uterus. Similar to the Women s Health Initiative (WHI), the ESPRIT trial found that long-term use of ET does not increase risk for breast cancer, with both of these large trials finding a reduced risk, contrasting with the findings of WHI and other large studies that have observed an increased risk of breast cancer with EPT. What prevents us from routinely recommending ET in symptomatic menopausal women with an intact uterus are concerns regarding endometrial cancer. With 2 years of unopposed ET and a protocol which employed endometrial biopsy with short-term cyclical progestin treatment in response to any reported bleeding, the long-term follow-up of the ESPRIT cohort found that 2 years of ET administered to women with an intact uterus did not increase the risk of endometrial cancer. Other placebo-controlled trials which employed 2 3 years of ET (either estradiol 1 mg or conjugated equine estrogen mg) in women with a uterus observed no cases of endometrial cancer in women randomised to ET (The Writing Group for the PEPI Trial. JAMA 1996;275:370 5; AZ Steiner, et al. Obstet Gynecol 2007; 109:581 7). The downside to prescribing ET when a uterus is present relates to uterine bleeding, the need for endometrial surveillance with vaginal ultrasound/endometrial biopsy, and the recognition that some women will develop endometrial hyperplasia, with a few likely undergoing hysterectomy should hyperplasia with atypia be found. Given these issues and the fact that EPT currently represents the standard of care for treatment of symptomatic women with a uterus (North American Menopause Society 2012; 19: ), most clinicians and women will be reluctant to choose ET when a uterus is present. However, some symptomatic women seeking hormonal management may be more concerned about the elevated risk of breast cancer with EPT than the potential for bleeding, vaginal ultrasound, endometrial biopsies and hyperplasia with ET. For such women, the findings of the ESPRIT and other trials indicate that several years of ET, with appropriate endometrial surveillance, represents a reasonable option. Future clinical trials should assess the endometrial safety of longer-term ET. Disclosure of interests Financial Support to the Department of Obstetrics and Gynecology, University of Florida College of Medicine-Jacksonville for Clinical Trials: Bayer, Endoceutics, Noven, Teva. Consultant (Advisory Boards): Actavis, Bayer, Merck, Teva.& ª 2014 Royal College of Obstetricians and Gynaecologists 705
Supplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationOestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial
Articles Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial The ESPRIT team* Summary Background Results of observational studies suggest that
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationLET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy
THERAPUTIC AGENTS: ARE THEY SAFE? Steven R. Goldstein, M.D. Professor of Obstetrics & Gynecology New York University School of Medicine Director of Gynecologic Ultrasound Co-Director of Bone Densitometry
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationDisclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent
17β Estradiol/Progesterone in a Single Oral Softgel Capsule (TX 001HR) Significantly Reduced Moderate to Severe Vasomotor Symptoms without Endometrial Hyperplasia Disclosures Research support: Actavis,
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationColumbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3
17β-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia Rogerio A Lobo, MD 1 ; David F Archer,
More informationSomething has changed? The literature from 2008 to present?
Something has changed? The literature from 2008 to present? Elina Hemminki National Institute for Health and Welfare, Helsinki, Finland Rome Oct 7, 2011: Post-menopausal hormone therapy and women's information
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationBreast cancer risk with postmenopausal hormonal treatment
Human Reproduction Update, Vol.11, No.6 pp. 545 56, 25 Advance Access publication September 8, 25 doi:1.193/humupd/dmi28 Breast cancer risk with postmenopausal hormonal treatment John A.Collins 1,2,5,
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationMenopausal hormone therapy includes various forms, Review
Review Annals of Internal Medicine Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Heidi
More informationHow HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationWomen s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School
Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationHormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationModeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L
Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy Mullins C D, Ohsfeldt R L Record Status This is a critical abstract of an economic
More information9/27/2017. Disclosure. Selecting Progestogens: Breast, Cardiovascular, and Cognitive Outcomes. James H Liu, MD. Overview
Disclosure Selecting Progestogens: Breast, Cardiovascular, and Cognitive utcomes James H Liu, MD Arthur H Bill Professor and Chair Departments of Reproductive Biology and bstetrics and Gynecology UH Cleveland
More informationTHE WOMEN S HEALTH INITIAtive
ORIGINAL CONTRIBUTION JAMA-EXPRESS Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women s Health Initiative Randomized Controlled Trial Writing
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationStatins are the most commonly used medications for
UPDATES ON AGING The Timing Hypothesis and Hormone Replacement Therapy: A Paradigm Shift in the Primary Prevention of Coronary Heart Disease in Women. Part 1: Comparison of Therapeutic Efficacy Howard
More informationThe Study of Tamoxifen and Raloxifene (STAR): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s The Study of Tamoxifen
More informationWARNING LETTER DEPARTMENT OF HEALTH & HUMAN SERVICES TRANSMITTED BY FACSIMILE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TRANSMITTED BY FACSIMILE Carole S. Ben-Maimon, M.D. President and Chief Operating Officer One
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationA cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W
A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation
More informationOB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.
OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of microwave endometrial ablation Introduction This overview has been prepared to assist
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationUPDATE: Women s Health Issues
UPDATE: Women s Health Issues Renee B. Alexis, MD, MBA, MPH, FACOG Associate Professor Department of OBGYN Kiran C. Patel College of Osteopathic Medicine Disclosure of Conflicts of Interest I have no financial
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationEstrogen (conjugated estrogens & ethinyl estradiol) Addition to the List
Estrogen (conjugated estrogens & ethinyl estradiol) Addition to the List Note: Commonly prescribed medication. Literature question Is estrogen effective and safe? Are conjugated estrogens effective and
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationMarco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa University Hospital Italy
La Terapia Ormonale Sostitutiva in Menopausa: Rivalutazione dei rischi e benefici nell ultimo decennio Marco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationEvidence Synthesis Number 93
Evidence Synthesis Number 93 Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationMENOPAUSAL HORMONE THERAPY 2016
MENOPAUSAL HORMONE THERAPY 2016 Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA NICE provides the National Health Service advice on effective, good value healthcare.
More informationNatural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationSouthern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3
The WISDOM survey: Physicians Level of Comfort Prescribing Treatment for Vulvar and Vaginal Atrophy (VVA) Symptoms in Women with a Predisposition or History of Breast Cancer Lisa Larkin, MD 1 ; Michael
More informationNorth American Menopause Society (NAMS)
North American Menopause Society (NAMS) 2012 Hormone Therapy Position Statement Cynthia B. Evans, MD Assistant Professor-Clinical Department of Obstetrics and Gynecology The Ohio State University College
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationTrial: Take-Home Message: Executive Summary: Guidelines:
Trial: Davies C, et al. "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial".
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationTHE SAFETY CHECK LIST BEFORE STARTING HT
THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 Revised November BENEFITS OF HRT
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 Revised November 2006 Published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationNIH Public Access Author Manuscript Clin Obstet Gynecol. Author manuscript; available in PMC 2009 October 21.
NIH Public Access Author Manuscript Published in final edited form as: Clin Obstet Gynecol. 2008 September ; 51(3): 564 580. doi:10.1097/grf.0b013e318181de86. Postmenopausal Hormone Therapy and Cardiovascular
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationPhysicians and their women patients have. Assessing benefits and risks of hormone therapy in 2008: New evidence, especially with regard to the heart
HOWARD N. HODIS, MD Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology, Professor of Medicine and Preventive Medicine, Professor of Molecular Pharmacology and Toxicology, Director, Atherosclerosis
More informationMenopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D
Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D Menopause and Cancer How does menopause affect a woman s cancer risk? Ø Menopause does not cause cancer.but risk of developing
More informationEvaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-004HR) in Menopausal Women with Moderate to Severe Dyspareunia
Evaluation of Systemic Effects of a Vaginal Estradiol Softgel Capsule Insert (TX-4HR) in Menopausal Women with Moderate to Severe Dyspareunia Lisa Larkin, MD 1 ; Andrew M Kaunitz, MD 2 ; James Liu, MD
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationPRE-ASS ESSMENT. Endometrial Ablation for Menorrhagia
PRE-ASS ESSMENT No. 30 Feb 2004 Before decides to undertake a health technology assessment, a pre-assessment of the literature is performed. Pre-assessments are based on a limited literature search; they
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationManagement of Perimenopausal symptoms
Management of Perimenopausal symptoms Serge Rozenberg CHU St Pierre Université libre de Bruxelles Belgium serge_rozenberg@stpierre-bru.be serge.rozenberg@skynet.be Conflict of interest & Disclosure Conflicts
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationPrior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD
Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,
More informationFinding Our Reasons to Choose Estrogen PRE- HRT. Learning Objectives. Disclosure. Learning Objectives. Replacement Therapy. For Previvors 6/1/17
Hormone Replacement Therapy Mefile:///Reimagined: How to Look Hot and Feel Healthy For Previvors Without Fear and Confusion Mache Seibel, MD HRT PRE- FOR VIVORS Mache Seibel, MD DrMache.com Disclosure
More information9: 3 TABLE OF CONTENTS P&T
Vol 9: No 3 TABLE OF CONTENTS Short-term Safety of Antipsychotics for Dementia 1-2 Preoperative Statins and Effects on Mortality 2-4 Hormone Replacement Therapy and Risk of Venous Thromboembolism 4-5 P&T
More informationPresentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy
Presentation to the Clinical Utility of Treating Patients with Compounded Bioidentical Hormone Therapy March 5, 2019 Nese Yuksel, BScPharm, PharmD, FCSHP, NCMP Professor Faculty of Pharmacy and Pharmaceutical
More informationSurveillance report Published: 17 March 2016 nice.org.uk
Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for
More informationSex, hormones and the heart
Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards
More informationHRT & Menopause Where Do We Stand Now?
HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by
More informationControversies in Primary Care Pros and Cons of HRT on patients with CHD
Controversies in Primary Care Pros and Cons of HRT on patients with CHD Claire Bellone MSc Clinical Nurse Specialist Menopause Nottingham Declaration Honorariums & Sponsorship from Bayer, Novonortis, Wyeth
More informationHeart Disease in Women: Is it Really Different?
Heart Disease in Women: Is it Really Different? Jennifer Jarbeau, MD Southcoast Physicians Group Cardiovascular Associates of RI Disclosures I have no financial interests to disclose I wish I did! Are
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More information